The purpose of this study is to look at the genetic changes that RAD001 causes in prostate
cancer cells and how those changes relate to patients' response to RAD001 treatment.
This correlative science study will be a minimum risk assessment of tumor and plasma samples
collected as part of a Phase II clinical trial of RAD001 in patients with HRPC. Prior to
enrollment or at the time of signing consent in the Phase II trial, patients will be
approached to participate in the correlative science study. Patients who agree to
participate will be assigned a separate study number which will be used to identify their
molecular, genetic, genomic and biomarker assessments using the tumor and plasma samples.
Clinical outcome results from the accompanying Phase II trial will be used for correlative
assessments in this study, however, results from this correlative science study will be kept
separate from the assessments and reporting of the clinical trial.
- Patients must be enrolled in the clinical study entitled: A Single Arm, Phase II
Study of RAD001 in Patients with Metastatic, Hormone-Refractory Prostate Cancer at
the time of enrollment onto this study.